View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Eramet : Informations relatives au nombre total de droits de vote et d...

Eramet : Informations relatives au nombre total de droits de vote et d’actions au 30 avril 2025 Dénomination sociale de l'émetteur : ERAMET SA10 boulevard de Grenelle75015 Paris632 045 381 RCS PARIS Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 223-8 II du code de commerce et l’article 223-16 du règlement général de l’Autorité des marchés financiers N° LEI : 549300LUH78PG2MP6N64 Date d'arrêté des informationsNombre total d'actions composant le capitalNombre total de droits de vote 30 avril 202528 755 047Nombre de droits de vote théoriques...

Eramet: 1 director

A director at Eramet bought 7,500 shares at 48.360EUR and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...

 PRESS RELEASE

Availability of the documents of the Ordinary and Extraordinary Shareh...

Availability of the documents of the Ordinary and Extraordinary Shareholders’ General Meeting to be held on May 26th, 2025 Paris, May 5th, 2025, 5:45 pm PRESS RELEASE Availability of the documents of the Ordinary and Extraordinary Shareholders’ General Meeting to be held on May 26th, 2025 Eramet’s shareholders are invited to participate in the Ordinary and Extraordinary Shareholder’s General Meeting, which will take place on: Monday, May 26th, 2025, at 10:00 a.m. (Paris time), at Eramet’s head office, 10 boulevard de Grenelle 75015 Paris. Detailed participation procedures are outlined...

 PRESS RELEASE

Mise à disposition des documents pour l’Assemblée Générale Ordinaire e...

Mise à disposition des documents pour l’Assemblée Générale Ordinaire et Extraordinaire du 26 mai 2025 Paris, le 5 mai 2025, 17h45 COMMUNIQUE DE PRESSE Mise à disposition des documents pour l’Assemblée Générale Ordinaire et Extraordinaire du 26 mai 2025 Les actionnaires de la société sont invités à participer à l’Assemblée Générale Ordinaire et Extraordinaire d’Eramet qui se tiendra le : Lundi 26 mai 2025 à 10h00, au siège social d’Eramet, 10 boulevard de Grenelle, 75015 Paris. Les modalités détaillées de participation figurent notamment dans la brochure de convocation et seront préci...

 PRESS RELEASE

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trial...

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment of 1,224 by 4%.Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week mainten...

Emna Ben Bdira ... (+2)
  • Emna Ben Bdira
  • Maxime Kogge
Emna Ben Bdira ... (+2)
  • Emna Ben Bdira
  • Maxime Kogge
Christophe Chaput
  • Christophe Chaput
Christophe Chaput
  • Christophe Chaput
Christophe Chaput
  • Christophe Chaput
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch